ODE II director
This article was originally published in The Tan Sheet
Executive Summary
FDA names Curtis Rosebraugh director of the Office of Drug Evaluation II after nine months as acting director of the office in the Center for Drug Evaluation and Research. He will oversee the divisions of Anesthesia, Analgesia and Rheumatology Products, Metabolism and Endocrinology Products and Pulmonary and Allergy Products. Rosebraugh from 2003-2005 served as deputy director of the Office of Nonprescription Products, with responsibilities including acting director of ONP's Division of Nonprescription Clinical Evaluation (1"The Tan Sheet" Feb. 10, 2003, In Brief). In 2005 he was named deputy director of the ODE II and became acting director in September 2007...
You may also be interested in...
New deputy in town
Curtis Rosebraugh, MD, took over as CDER Division of OTC Drug Products deputy director effective Jan. 27. Rosebraugh has previously worked as a medical officer in the Division of Pulmonary & Allergy Drug Products, which could affect the extent to which the OTC drug division attempts to initiate Rx-to-OTC switches of the remaining second-generation antihistamines. Rosebraugh replaces Linda Katz, MD, who left to head the Office of Cosmetics & Colors Sept. 3. Rosebraugh will report to Division of OTC Drug Products Director Charles Ganley, MD...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.